Helpful videos

Image onscreen:
A purple background featuring headshots of three people. From left to right, the photos are labeled with the names: Dr. Angela Hirbe, Austin, and Tara Herington.

Text onscreen:
See beyond the limits of NF1-PN
Learn about a treatment for adults and children

Image onscreen:
Screen transitions to a presentation slide featuring the headshot of Dr. Hirbe.

Text onscreen:
Chapter 1: An Overview of GOMEKLI
Dr. Angela Hirbe
GOMEKLI study investigator and Austin's doctor; Washington University School of Medicine, St. Louis

[Dr. Hirbe]
Welcome, everybody. We're excited to have you here today. My name is Angie Hirbe and I will be one of the presenters today.

The presentation is sponsored by SpringWorks Therapeutics. And they're committed to developing therapies for patients with rare diseases. So, very happy to deliver this much-needed treatment option, GOMEKLI, or mirdametinib.

GOMEKLI is the first FDA-approved treatment for both adults and children with NF1 plexiform neurofibromas. I will give an overview of GOMEKLI and kind of talk about some of the clinical trial data as well as dosing and administration.

And then I'll hand things over to our GOMEKLI patient ambassador, Austin, who's one of our patients. He'll talk about his experience with living with NF1-PN and being on GOMEKLI. And then, finally, Tara will talk about the SpringWorks CareConnections® patient support program.

So we will get started.

So first, I'm just kind of going to go over some of the safety information and I'll talk a little bit about it more later. But just, you know, very brief overview.

You know, before taking GOMEKLI then you need to obviously talk to your physician about any conditions that you have, but especially if there are any eye problems, heart problems, or thoughts about becoming pregnant because there can obviously be side effects to any medication for an unborn baby.

So again, there's information here. For females, if you're going to become pregnant, then obviously again, you want to talk to your physician first.

And then it's also very important to talk to your healthcare provider about any medications that you take, and that includes prescription medications as well as over-the-counter medications, because all of these things can have drug interactions.

And so we as providers need to be aware of that so we can make sure that the medication is safe.

Again, possible side effects. And I'll go into some of this later on too, when talking about the clinical trial data.

But, you know, we worry about a couple serious side effects that are not common, but certainly serious. And so you need to be aware of these things.

So eye problems are one. Anytime you know, you would experience any blurry vision, loss of vision, changes in vision that needs to be reported to your physician right away.

Heart problems. We know that GOMEKLI has, or any MEK inhibitor has, been shown to potentially decrease the pumping function of the heart, something we call the ejection fraction. And so, it's very common for us to get an echocardiogram as a special ultrasound of the heart. So we know what the pumping function is at baseline. And then we monitor that pumping function throughout treatment with the medication.

So side effects that you worry about that would alert you to that are things like coughing, shortness of breath, fluid, swelling. So swelling in your feet or your ankles, or increase in heart rate. And then skin problems.

So rashes are actually common with any MEK inhibitor including GOMEKLI. But sometimes these can be severe. So anytime you have any kind of skin changes, that's also something that you should talk to your physician about early. We always like to treat things early before they become a big problem.

So what is an NF1 plexiform neurofibroma? So, we know that NF1 is a genetic condition.

It's actually the most common tumor predisposition syndrome, and it affects about one in 2500 people worldwide. Plexiform neurofibromas are tumors that can form in in patients with NF1 and about 50% of patients with NF1 will develop these plexiform neurofibromas. And these are different from other neurofibromas.

So plexiform neurofibromas are, they tend to be bigger tumors.

And they arise from multiple nerve roots. So these are different than the cutaneous neurofibromas that are on the skin or the subcutaneous neurofibromas that are right under the skin.

So what are the most common symptoms of NF1 plexiform neurofibromas?

And so, you know, the things that, you know, our patients will notice the most are pain, difficulty moving around, sometimes because of the location of the tumor and how bulky it is, sometimes because of pain or changes in appearance.

So some of the larger tumors, can obviously be disfiguring or, you know, can make things like wearing clothes difficult, depending on the bulkiness of the tumors.

But they can also impact things like vision, hearing, or breathing depending on where they are.

And we know that 85% of these tumors And we know that 85% of these tumors cannot be completely removed by surgery. And often when patients have debulking surgeries, unfortunately, the tumors will grow back. So GOMEKLI or mirdametinib is the first FDA-approved medication proven to shrink plexiforms in both adults and children with NF1 plexiform neurofibromas.

And this drug is something called a MEK inhibitor.

So this is a targeted drug meaning it's kind of going after one specific pathway in a tumor cell, not a traditional chemotherapy, where I think of chemotherapy as like big guns that are just going after, you know, rapidly growing cells and have lots and lots of side effects.

The MEK inhibitor, you know, we know with patients with NF1, you have a mutation or loss of that NF1 gene. And NF1 is something that's an important stop sign in our cells.

So it tells them to stop growing.

And so the MEK inhibitor, while we can't replace NF1 it kind of helps to put a stop sign back into the cells to help to tell them to stop growing.

So I'm going to go over some of the data from the clinical trial.

So GOMEKLI was studied in one of the largest clinical trials for NF1 plexiform neurofibromas. So this was a single-arm trial that included 114 So this was a single-arm trial that included 114 patients with NF1 plexiform neurofibromas.

So there were 58 adults. So those are patients over the age of 18 and then 56 children. So those are kiddos from the age range of 2 to 17.

And at the start of the trial, pain and changes in appearance were really the most common plexiform neurofibroma-related symptoms that were reported. So before enrolling in the trial, 69% of adults and 36% of children and adolescents had tried surgery to remove their plexiform neurofibromas before.

So again, this is the first treatment proven to shrink tumors in both well, really in adults with plexiform neurofibromas, it’s the first.

So if you look at this slide here, so 41% of adult patients, so that’s 24 out of 58 that were treated with GOMEKLI had their plexiform neurofibromas shrink by at least 20%.

And so the little circles are supposed to give you kind of some guide to see, what is 20% shrinkage?

So if you think of that circle as a plexiform neurofibroma before starting GOMEKLI, being 20% smaller would make the circle look like that.

And then of those patients who had their tumor shrink, 15 of them really saw their plexiform shrink by more than 50%.

And so, again, drawing your attention to the next circle on there kind of shows you what is 50% smaller if we're pretending the plexiform is a perfect circle.

And that reduction in plexiform neurofibroma size was confirmed on later MRI or magnetic resonance imaging scans.

And that 50% reduction was something that we call an exploratory analysis meaning it wasn't specifically designed in advance in the protocol.

The real endpoint was that 20% smaller. So in adults who benefited from GOMEKLI, the plexiform started to shrink within months, not weeks.

So we tried to set the appropriate expectation for patients. So, these these drugs don't have an effect immediately.

But if we look at the data by about four months, 46% of the patients saw results, and then by 12 months, 71%.

So 17 out of the 24 that that had shrinkage saw results.

So if we think about that age range, or the range in which that happens.

So when adults that benefited from treatment, plexiforms began to shrink by at least 20%, for some patients by four months.

But the range is pretty big.

So some patients didn't see that effect until being on the medicine for 19 months, and then the median or the middle amount of time that it took for the plexiforms to begin shrinking was 7.8 months.

So you need to think about that when you're starting therapy, that it may take a while before you see a benefit.

So, it's one of the reasons why we try to work really hard to make the side effects manageable so that we can know whether or not a patient has a benefit from the medication.

And the clinical trial was for two years long, and after that, 84% of adults chose to keep taking the medication in an optional long-term follow-up portion of the study. So again, the medication has also been proven to shrink plexiforms in children and adolescents with NF1 plexiform neurofibromas.

So 52% of the children, so that's 29 out of 56 saw their tumors shrink by at least 20%.

And so again, I have the circles here so you can remember, what does 20% look like?

And then 15 of those children saw their plexiform neurofibromas shrink by more than 50%.

So again, 50% smaller if we're pretending these are perfect circles.

And again these were confirmed on later imaging scans. And then the time frame for expecting a response is similar in the children as it is in the adults.

So again 45%.

So 13 out of 29 of the patients saw results after four months on therapy, and 83%, so it’s 24 out of the 29 patients saw results by about a year.

And that middle time point, you know, the median amount of time that it takes for the plexiforms to shrink was the same in kiddos. So about 7.9 months.

And again that range is 4 to 19 months. So it may take some time before patients see a response.

So it may take some time before patients see a response.

So kind of going through, what are the most common side effects that we see?

The most common things that we see in adults and children are diarrhea. And that does respond pretty well to Imodium, nausea, sometimes some muscle or joint pain, and then vomiting.

Adults also tended to complain of some tiredness or fatigue.

And children and adolescents, the sort of more common things that we saw are sometimes just stomachaches, so abdominal pain, headaches.

And then the rash that you see in children and adults is a little bit different.

So in adults, we see more of this acne-like rash, and kiddos, it tended to be, sometimes just some skin redness and then something called a paronychia, which is where you get this swelling or pain around the fingernails or the toes.

And then one of the most common lab abnormalities that we see is an elevation in something called CPK.

And this is an enzyme and it's in your muscles and, so sometimes, you know, we would see an increase in this lab test.

And most often, you know, it doesn't mean anything and patients don’t have any symptoms but it is something that we do need to keep an eye on.

Because if it gets super high, sometimes that protein can clog the kidneys, and that can cause problems.

But actually having a problem, you know, from this lab abnormality was exceedingly uncommon in the trial.

And then some children also experience a decrease in their white blood cell count, specifically the neutrophils.

And these are cells that are important to fight infection. But despite that lab abnormality, there weren't, you know, increased infections or anything like that in the kiddos.

And then again, the serious side effects.

So the eye problems, we always want to know if a patient has any vision changes, and we do make sure that patients get their vision monitored during treatment.

Heart problems, we talked about before. These medications can affect the pumping function of the heart. So it's something that we keep a close eye on.

And then skin problems.

Rashes are pretty common in kids and adults, so the rash is different in children versus adults.

And most of the time the rashes are not serious, but they can be.

So it's important to talk about things up front, so that they can be addressed.

So among adults, about 22% of patients did stop treatment due to a side effect.

That number was smaller in children, so only about 9% stopped treatment due to a side effect.

And then if we look, what do these pills look like and how are they taken?

GOMEKLI comes in two different forms. So there is a grape-flavored tablet that you can make an oral suspension with.

So that can dissolve in liquid.

And so it can be taken that way.

So for younger children who can't swallow pills, or even for some adult patients who may have difficulty swallowing pills, that is an option for patients.

And then there's also capsules that come in two different sizes, so a 1-mg smaller capsule and then a 2-mg capsule.

The medication is taken by mouth, you know, twice a day, so about 12 hours apart.

It can be taken with or without food. And then again we look at side effects in terms of, you know, deciding whether or not a patient is benefiting and should stay on, on medication.

So there's also a built-in treatment break with GOMEKLI.

So if you look at how the medication is taken, the dosing cycle is 28 days or four weeks, but the actual medication is taken twice a day for the first three weeks, or 21 days.

And then, you get seven days where the medication is not taken, so that's that treatment-free week, and then the cycle starts over again.

So I will stop there and turn it over to Austin.

Image onscreen:
Screen transitions to a presentation slide featuring the headshot of Austin.

Text onscreen:
Chapter 2: My GOMEKLI story
Austin
GOMEKLI Patient Ambassador; currently on treatment

[Austin]
Hello! My name is Austin. I'd like to thank SpringWorks Therapeutics for sponsoring me for me to share my story with you all here today about living with neurofibromatosis type 1 with plexiform neurofibromas or NF1-PNs, and being treated with GOMEKLI or mirdametinib.

So when I was two and a half years old, my parents noticed a large discoloration on my back that resembled a bruise like, at first they just thought it was, they thought it was a bruise.

I have a brother that's 11 months older than me, and they thought my brother sat on me. You know how boys will be boys. But after it didn't go away for a few weeks, they grew some more concerns.

And, they took me to the doctor, and I -- we found out it was a tumor. My father and paternal grandmother both have neurofibromatosis type 1. We were kind of worried that I would have a predisposition of being able to get that.

Because of this my family is always aware of the possibility of NF1 being passed on to me.

While they had some understanding of NF1, they weren’t really prepared for exactly how serious this was.

When we learned that that bruise was a tumor, I went in for a lot of testing. I was much too young to remember exactly what everything we did. But when I was diagnosed with that plexiform, from that point on, my life totally changed.

Especially in my toddler years when I was going to a lot of doctor visits, being monitored, dealing with a lot of back pain. And we even actually ended up giving my tumor a nickname, “Ralph, the runaway mouse,” after the old children's book that I loved. So my doctors warned my parents that the tumor could grow And if it did grow, I would more than likely have to undergo surgery to remove part of it or debulk it, which was high risk due to several complications, especially because it was growing around a lot of key nerves.

Especially the nerves that would help me walk. Lo and behold, the doctors were right and two years later, the tumor was now the size, was now a great a good size. and I would have to have surgery to get it removed.

On February 2nd of 2000, 2/2 of 2000, at four and a half years old, when you know you're a kid, supposed to be learning how to ride a bike, swim and have fun on the playground, I was undergoing my first major surgery. Only part of the tumor was removed, otherwise it would have paralyzed me from the waist down. The portion of the tumor that was removed was the size of a foam football.

So imagine about a four-year-old kid and a foam football being removed from their back.

It weighed about 20% of my body weight at the time. After that surgery, I was bedridden for quite some time.

And just ten months later, after continuing to be monitoring, we found out that it was growing back into my spine and we had to have a second surgery. This time they removed a portion that was the size of a golf ball. Now you may think I was a little too young to understand everything that was happening to me, but both my parents were in the first-responder field.

My father was a firefighter/EMT, and my mother was a nurse. They taught me the importance of self-advocation even at such a young age. Doctors would want to pull my parents out of the room and talk to me about the seriousness of what was going on and making these key decisions, and they would flat out tell them, “No, Austin has to live with us his entire life.” He needs to be part of these decisions to know what's going on.

And especially because now I had that giant scar and you could see my tumor.

You know, other kids would see it at the pool or something and I could just explain to them.

With this, I also had many limitations.

My memories growing up included a lot of sitting on the sidelines of playing sports or on the playground when kids would run around having fun, including my older brother and my younger sister. My pain was very unpredictable. When I could try to participate at times, and I would, but then I'd have to go sit down because of how bad my back would start to hurt, and I would sometimes just lie down in the grass.

At school, I tried my best to fit in with my peers and participate in gym or outside at recess, but it didn't always work out right.

When most kids would play sports or did some fun extracurricular activities, I wasn't able to do much of those.

Between my severe pain, the doctor's appointments, and just everything that was going on, I struggled. And this also kind of struggled to help me focus on my studies at times as well, let alone even have a social life.

The worst part was growing up with two siblings who didn't have the same limitations as me. I couldn't help feeling left out at times because they were able to do everything at a more advanced pace than I could.

I was living a completely different life from them. It was a battle to try to get them to understand that I wasn't lazy, or that I didn't want to do something, it's just that I couldn't do something.

And this even went on into my school years with teachers or, you know, friends’ parents as well. But even from the sidelines, I was always teaching others about my NF1-PNs.

My parents said that if someone made fun of me, I should use that opportunity to educate them because them poking fun or making fun of me was them just the lack of them understanding.

So as I grew up, my pain levels would vary.

There were times when my pain was uncontrollable, where I could barely move or get out of bed, or to where I would be in the hospital for several weeks in pain. I saw several doctors, including pediatricians, pain management doctors, and NF specialists. We would try over-the-counter pain medications to help manage my pain, but it didn't always work.

And by the time I was 18, however, I kind of had a new tide. I was in a little bit less pain, so I thought it all was doing a lot better.

I decided to take a break because I was tired of seeing doctors all the time and going to appointments and medical treatments and all that, and I was 18.

I was an adult now. I thought I can make my own decisions and I just wanted to feel free and normal for a change. So after graduating high school, no longer dealing with that, I decided to chase one of my biggest dreams.

Like my parents dedication to serve others in their career, I was determined to join the military. Unfortunately, with my tumors, I could not join the military. So I did the next best thing and I went into a law enforcement career.

I tried my best to get through that. I could not advance in my career because of my pain, but I didn't let it stop me from at least trying and helping others along my way.

I started off in corrections, then I moved up to be a deputy sheriff, where I was a bailiff, and then I became a public safety officer.

And then things got worse again, where my pain came back full-fledge force.

It was just relentless. I was about 22 years old when that severe pain came back, and it just started where I could barely move, let alone do my job. I knew it was time to see a doctor again.

And with my mobility issues starting to take over, starting to be worse, I was taking more over-the-counter pain medications, so I knew it was the right time.

For six years, I proudly wore my badge, but the pain eventually just became too much and I had to step away from that career.

It was more than just leaving a job for me. It was leaving a calling in something that I had worked hard for.

I knew I couldn't live like this anymore with my severe pain, and as I even struggled to have a job in retail at that point, I think back on it and I do regret my decision to stop seeing my doctor. And I still wonder that if I stopped, if I didn't stop, maybe I could have furthered my career and have less pain in the long run. But that's neither here nor there.

When I got back in to see my doctor, we both agreed it was a good time for me to start treatment for my NF1-PN, so my primary doctor referred me to an oncologist.

So I went to her office, eager and hopeful to start a new journey on my NF1-PN.

And then during the appointment, my oncologist mentioned a clinical trial that was coming up for a medication called mirdametinib, or now, GOMEKLI.

She explained that the goal of the trial was to decrease the tumor size by at least 20% in adults and children two and older. So in about 2020, once we learned that I qualified for the trial, we got started.

I take GOMEKLI twice a day, oral pill, for 21 days, and then I'm off it for seven.

Since starting GOMEKLI I have experienced some of those side effects.

At the start, the side effects seemed a little more worse, but now they're a lot more minimal.

One of the biggest side effects I had was the skin rash, which was almost to me, it seemed more like looked like a, poison ivy. But it wasn't.

And I used baby lotion and it kind of soothed the itching and helped it out. At least that's for me personally. For everybody else, it may be different. And definitely consult your doctor.

So, and then at the one-year mark, after going through all these testings every couple months and to the doctor always, I was kind of tired of it again.

And I seriously considered stopping it just because it was kind of a struggle to get to the doctor all the time and put my life on hold just to do two days' worth of doctor's appointments between the testing and then the doctor.

So I talked to my mom about that, and I told her that I was thinking about it, depending on what the results were, and my mom said it was my decision.

Well, we went to the doctor's office, and we sat down, and when Doctor Hirbe got in there and I was speechless because what she told us was my tumor shrank 57% in the first year.

[applause] Yeah, I, I just could not say a word. And I remember my mom turning to me and just saying, “Well, that answers your question about whether you should stay on the treatment or not.” So that moment marked a turning point for me.

For years I'd seen my NF1-PN as a burden, but hearing that my tumor was actually shrinking, I felt like I had a completely new outlook.

Again, this is just my experience and others' may be different, but it gave me a little more hope in my life that if that could change, what else could change in my life?

My oncologist and I both agreed that GOMEKLI was working, and I would stay on it as a part of a long-term, optional, follow-up phase of the study, and I've now been on it for a little over five years. Through my journey with NF1-PN, I've given up a lot in my life. I had to give up my goal of going into the military, my law enforcement profession.

But I have found a new purpose, one that's allowed me to connect my career to serving people.

One that I thought about doing for a long time as well, I became involved in ministry. I'm a pastor, and I stepped into the role earlier this year as a full time pastor, and it's been one of my proudest achievements, and I'm now thankful to be able to offer guidance and support to others in their lives. The flexibility ...

[applause] Thank you, yeah. And the flexibility of this role has also allowed me to continue my doctor's appointments to help me easily manage my NF1-PN, and also be able to help other people as well.

I now know how important it is to stay on top of my care and continue to monitor my NF1-PNs even when it doesn't seem as severe. I see my oncologist about every three months and my pain management specialists every six months. My oncologist and her team are great.

She's very approachable, easy to talk to, and she's like family. We can joke around when the moment calls for it, but we can also get, shift to serious topics when needed.

One of the most recent examples is I got a bad sunburn on my right arm. I'm not going to hear the end of that. Five minutes.

Yes, five minutes ago. But she's always ready to help me find a solution to any of my problems.

And if she doesn't have an answer for me, she’s always spot on with me with honesty and always will get back with me in a timely manner. Since I've dealt with NF1-PN my entire life, I feel that I'm pretty knowledgeable about it, allowing me to have more advanced conversations around this. Of course, I have my parents to thank for that because at a young age, being able to self-advocate and take charge of my own care.

To own your own care is probably one of the most important things any of us can do with NF1, especially with PNs. I've had to accept my own limitations in life, which are things I tend to challenge maybe a little more than I should. But I do love the outdoors: camping, hunting, hiking, fishing, and unfortunately, not all those activities are easy to do with my NF1-PNs, especially when I have a spike in my pain.

But I've learned to manage the best I can, and go through working with my doctor and taking my medications to be able to afford me more opportunities to partake in the things I love to do.

I often heard patients with NF1-PN use the words “adapt” and “cope,” and that is what SpringWorks Therapeutics researchers have worked to help patients do, and I'm thankful for them. I know what it's like to feel limited, to sit on the sidelines, to struggle with pain and and to miss out on my dreams, but to find new ones.

And that gives you the hope. To anyone struggling with your own NF1-PN journey, you're not alone. Your path may not look the way you imagined, but there's still a future worth fighting for.

And with all of us together behind you, we can do it together. Thank you.

Image onscreen:
Screen transitions to a presentation slide featuring the headshot of Tara Herington.

Text onscreen:
Chapter 3: A Look at SpringWorks CareConnections®
Tara Herington
Executive Director, Global Patient Access at SpringWorks Therapeutics

[Tara Herington]
So I'm here to talk about our SpringWorks CareConnections® support program that supports people who are starting on GOMEKLI or staying on GOMEKLI.

So this is a personalized support program. You'll hear me say “personalized” a lot.

And it's a free program, and it's for insurance navigation. So we all know that can be a little tricky.

There's also financial assistance that we offer.

And we also have personalized educational and emotional support with our nurses.

And so I'll go into each of these three things in more detail.

How many people have really struggled with insurance before? I know I have and just trying to figure things out. So one of the things we do is we have a team that really looks into the benefits, figures out if it's covered, if it's not covered, how much the copay will be, is there any deductible remaining?

Just all of those out-of-pocket costs and figures all that out. And then the next step would also be doing a prior authorization.

Almost always I'll have to say a prior authorization is needed. And then if the prior authorization is denied, then we also have the ability to work through the appeal process.

And we have a lot of tools available for patients and for their HCPs, for their healthcare providers, to support that. And then we also have financial assistance.

The financial assistance, we have a copay, offering a commercial copay offering. It's a $0 copay card. So for the 21-day supply, I always say $0; free is my favorite color.

So we have our copay program.

We also have a program to help because we know it's not just the medication.

There are also other out-of-pocket costs that are associated with being on a medication.

And so we also have coverage for that, for eligible visits, for examinations. It can be a visit to a specialist.

It can be testing...things like that. And so I know your next question is going to be, okay, what are the…what's the eligibility?

So we do have some different criteria.

So it's for residents of the United States or its territories or possessions.

Also this is for the copay program, for the 21-day supply, for the $0.

It's commercially insured. So usually we think of that as if you have insurance through your employer. So not Medicare, not Medicaid, through your employer.

A prescription, of course, for GOMEKLI, a copay greater than zero and then also for that insurance coverage.

If, we do have…sometimes we find folks who still struggle with affordability even after all this, we have other programs, too, that are available to folks.

And the way to know about those is through our the nurse navigators that we have. And I'll go into the Nurse Advocates in just a minute. But there are a couple of QR codes that we have.

So there's one up here.

So, that you'll see there's another one later. So if you get your phones out and want to take advantage of that, I just want to make sure that you're ready.

So our Nurse Advocates were designed to be a single point of contact to work with people who are starting on or staying GOMEKLI and their family members or loved ones.

And so this is the person that you'll meet, when first being enrolled in the program, and they work with folks from the very beginning all the way through.

And this could be anything with, you know, like how to take the medication as prescribed. They're all trained in NF1-PN, and of course, they're all trained on GOMEKLI. Many had experience with NF1-PN prior to joining our program.

So they also could answer questions about disease state, things about managing treatment over time.

Sometimes people have, oh gosh, maybe they're starting a new job, and they have new insurance and they want to know how will this work with my new insurance?

Will I still be able to stay on GOMEKLI? So they can help through that.

And then also help plan conversations with the care team.

When the patients and the Nurse Advocates are talking together, the Nurse Advocate may say, “Hey, that's a great point to bring up with your doctor. Make sure you write that down so you have it during the next visit.” So they really are there all the way through, every step of the way.

And then we also have something new that we just brought out really recently and we're excited about it, and this is our Digital Companion.

So you may be familiar with Medisafe. We've partnered with Medisafe. Medisafe is a, it's a health tracker, a really robust health tracker. I know I like to use it for keeping things like, you know, all the different doctor's appointments I may have, things like, just lab results.

It just keeps everything right there in your phone, which we always have with us all the time. And then we've created some customized support through the Medisafe app that's specific to GOMEKLI.

So that means there are specific medication reminders for the three weeks on, the one week off.

We also have access to educational content that's specific to GOMEKLI.

You could even reach out and, reach out to your Nurse Advocate through the Digital Companion. So it's a really nice offering for folks who are taking GOMEKLI.

And so, with that I’d like to, on behalf of SpringWorks, really thank you for your attention today. You've been great. Thank you so much to Doctor Hirbe and to Austin for sharing your story. That was that was great. You can also go to GOMEKLI.com to get more information.

Image onscreen:
Photo of a couple dancing to a live band appears alongside a QR code to GOMEKLI.com.

Text onscreen:
Thank you!
Learn more at GOMEKLI.com

Image onscreen:
SpringWorks logo and GOMEKLI logo appear.

Text onscreen:
©2025 SpringWorks Therapeutics, Inc. All rights reserved. GOMEKLI and SpringWorks CareConnections are registered trademarks of SpringWorks Therapeutics, Inc. All other trademarks and logos are property of their respective owners. C_GOM_US_0428 8/25